This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the…
Reuters Health Information